Anavex Life Sciences Corp (AVXL)

[nidan7500]

If new FDA guidelines require more comprehensive analysis and planning prior to P2/P3 then micro Biotec investing should be lower risk than in past. In fact, an objective retrospective review of the past 20+ yrs of AD trials data w/new analysis algo's would (should) show what is now obvious. They never had a chance.

A lot of money and lives has been lost. We owe it to ourselves and patients lost to at least be honest and learn from the technical and procedural missteps by doing a decent failure analysis. I would like to think that the planned/hyped A2-73 new FDA trials are delayed b/c something wonderful happened(in the cloud) during the trials planning/analysis.

And for those who hype risks and enjoy playing dishonest mind games, pay no attention to this post.